"The project will expand St. Luke's services related to heart and vascular health, neurosciences, and cancer care."
Architectural Nexus’ Post
More Relevant Posts
-
NEWS: Construction Underway for Michigan State University + Henry Ford Health Biomedical Research Center -- Michigan State University (MSU) and Henry Ford Health have joined forces to construct the $335 million Henry Ford Health + Michigan State University Research Center, which will house 84 principal investigators and their research teams focused on cancer, neuroscience, infectious diseases, immunology, and public health. The first floor will accommodate a large core lab including an imaging suite. An entire floor will be dedicated to the Nick Gilbert Neurofibromatosis Research Institute. At 335,000 sf and seven stories, it will be will be MSU’s largest research facility. As part of a 30-year partnership begun in 2021, the center will be owned by MSU on land leased from Henry Ford Health, and operated jointly by both institutions. The venture is part of a $3 billion development group that includes the Detroit Pistons basketball organization. The “Future of Health” project will feature a new hospital tower and 600 units of mixed-income housing. Designed by ZGF Architects with Barton Malow as the construction manager, the facility is expected to open in 2027. https://lnkd.in/eRX6QcSU #Collaboration #GroundBreaking #InterdisciplinaryResearch #Biomedical #Healthcare #HigherEducation #ResearchandDevelopment
Construction Underway for Michigan State University + Henry Ford Health Biomedical Research Center
tradelineinc.com
To view or add a comment, sign in
-
Looking forward to results of these studies
We are thrilled to announce the winners of our Clinical Trial Sponsorship Program! After a comprehensive selection process by an expert jury panel, we are pleased to recognize the exceptional research proposals from: - Dr. Liqi Shu and a multidisciplinary team from Brown University and Rhode Island Hospital, USA, for their project "Efficacy of Portable EEG Technology in Prehospital Triage of Large Vessel Occlusion Strokes" - Marc Van Hulle, Ph.D. and Arne Van Den Kerchove, Ph.D. from KU Leuven, Belgium, for their project "Gaze-independent Visual Brain-Computer Interface for Use by Patients with Limited or No Eye Control" - Dr. Marcus C. Ng from the University of Manitoba, Canada, for his project "The Far-north Remote Online Zeto Electroencephalography (F.R.O.Z.E.) Trial" These teams are conducting groundbreaking #research aimed at improving patient care. We are excited to support their innovative projects and look forward to the advancements they will bring to the field. Read more: https://lnkd.in/gEz39eP7 #clinicaltrial #medicalresearch #neuroscience
To view or add a comment, sign in
-
Child Neurology and Neurodevelopmental disorders resident, Boston Children's Hospital, Harvard Medical School. Clinical Research Fellow, FNNDSC, Boston Children's Hospital, Harvard Medical School.
Using AI and functional connectivity on scalp EEG to delineate the epileptogebic zone. Our new paper is out on Epilepsia, #ILAE ! Congratulations to the whole team at Boston Children's Hospital Neurology, #FNNDSC and especially to Eleonora Tamilia and to Navaneethakrishna Makaram! #epilepsy #medicalresearch #childneurology #ndd #residency #FNNDSC #artificialintelligence #epilepsia #ilae https://lnkd.in/ebFm-HJ4
Assistant Professor of Pediatrics at Harvard Medical School; Research Scientist at Boston Children's Hospital
Our paper "Interictal EEG source connectivity to localize the epileptogenic zone in patients with drug-resistant epilepsy: A machine learning approach" has been published today on 'Epilepsia'! Kudos to Georgios Ntolkeras for his perseverance and hard work! Congrats to the whole team, particularly to all the mentees and alumni who also put a lot of hard work on this project. Navaneethakrishna Makaram Matteo Bernabei Aimé De la Vega Boston Children's Hospital
Interictal EEG source connectivity to localize the epileptogenic zone in patients with drug‐resistant epilepsy: A machine learning approach
onlinelibrary.wiley.com
To view or add a comment, sign in
-
🌟 Spotlight on Dr. Greer Waldrop! 🌟 We're excited to highlight Dr. Greer Waldrop from The University of California, San Francisco, one of the recipients of the FSR Sarcoidosis Research Fellowship Grant. Her project, titled "Defining Neurosarcoidosis: From Disease Activity to the CNS Transcriptome," is set to revolutionize our understanding of neurosarcoidosis. Dr. Waldrop's research aims to fill crucial gaps in the field by creating a standardized framework for classifying disease activity and conducting the first-ever transcriptomic analysis from the central nervous system. This groundbreaking work will enhance our understanding of neurosarcoidosis and pave the way for better diagnostic and therapeutic strategies. Join us in celebrating Dr. Waldrop's dedication to advancing sarcoidosis research and the significant impact her work will have on patients' lives. 🎉 #Neurosarcoidosis #SarcoidosisResearch #FSRFellowship #InnovativeResearch #StopSarcoidosis
To view or add a comment, sign in
-
-
Nice! From Naveen Rao’s coverage of neurotech at #jpm2024: “What Is Neurotech’s ‘Killer App’? For JPM’s biotech attendees, a neurotechnology home run would be a reliable diagnostic test (like a set of biomarkers) for earlier detection of mild cognitive impairment and/or Alzheimer's disease.” https://lnkd.in/giHxqNZM At Kernel, we’re applying our one-of-a-kind neurotechnology (Kernel Flow) and working with our clinical research partners to build an early detection biomarker for MCI…. And seeing promising results! https://lnkd.in/gviSWniN
Neurotech Takes The Stage At JPM 2024
forbes.com
To view or add a comment, sign in
-
🧠 Poietis Partners in the Groundbreaking 4-DBR Project 🧠 We are proud to be partner in the 4-Deep Brain Reconstruction (4-DBR) initiative, a Horizon European Innovation Council (EIC) Pathfinder Open project aimed at revolutionizing the treatment of neurodegenerative disorders. 🔗https://www.4dbr.eu/ The 4-DBR project is a collaborative effort to develop a conceptually novel approach for brain reconstruction, seeking to provide a groundbreaking solution for patients suffering from conditions that currently have limited treatment options. 🎥 As part of this collaboration, we're excited to share the project's launch video, offering a window into the innovative strategies we're exploring together. 📅 This coming Thursday marks an important milestone as we head into the annual consortium meeting for the 4-DBR project. Fabien Guillemot and Deepshika Arasu from Poietis, will participate and contribute to the discussions that will shape the future of this ambitious project. #4DBR #Poietis #NeurodegenerativeDiseases #HorizonEurope #Bioprinting #HealthcareInnovation #ScienceandTechnology #ConsortiumMeeting
4-Deep Brain Reconstruction (4-DBR) / project's video
To view or add a comment, sign in
-
Project Spotlight: PREBO-6 Dive into the pioneering research happening at Herston Imaging Research Facility with Child Health Research Centre The University of Queensland for PREBO-6! Our team is at the forefront of predicting childhood brain outcomes in preterm infants using neonatal MRI and clinical biomarkers. By combining advanced imaging techniques with clinical assessments, we're aiming to identify infants at risk of adverse neurodevelopmental outcomes early on. This study, focusing on a cohort of very preterm infants at 6 years CA, holds immense promise in informing prognosis and guiding interventions. Plus, our cutting-edge MRI imaging techniques, including motion-correcting WIP ABCD C2P sequences, ensure high-quality data even in non-compliant patients like children. #PREBO6 #ChildhoodBrainOutcomes #NeonatalMRI #ResearchInnovation
To view or add a comment, sign in
-
-
Yes, you’re correct. Neurosurgeon Craig van Horne is indeed pioneering a new approach to potentially slow or reverse the progression of Parkinson’s disease. This approach, known as DBS+ (Deep Brain Stimulation Plus), combines the established treatment for advanced Parkinson’s, which is an electrode-implanting surgery known as Deep Brain Stimulation (DBS), with an experimental nerve-grafting procedure. In DBS+, the surgeon transplants peripheral nerve tissue into an area of the brain where neurons are dying. The grafted cells are being tested for their ability to release chemicals believed to rejuvenate the brain’s weary dopamine-producing neurons1. Peripheral nerves, which lie outside the brain and spinal cord, have regenerative qualities that nerves inside the brain do not. The UK team hopes to leverage those regenerative effects within the brain, potentially halting or reversing nerve damage caused by Parkinson’s. The DBS+ procedure has been performed in 60 patients, with initial results of the Phase 1 study being highly encouraging. Early participants have shown a clinically important improvement in symptoms, marked by a decrease in scores on the UPDRS (Unified Parkinson’s Disease Rating Scale) – the most widely used clinical rating scale for Parkinson’s. #consultantemerfalen #consultancyemerfalen
Neurosurgeon Craig van Horne is pioneering a new approach to potentially slow or reverse the progression of this incurable disease, inspired by his early undergraduate research experience at the MBL.
From Basics to Bedside: How MBL Research Fueled Applications to Treat Parkinson's Disease | Marine Biological Laboratory
mbl.edu
To view or add a comment, sign in
-
If you are interested in the role of IFN type I signalling in the brain, like me, then this recent publication will interest you. 🧠 Ethan R. Roy et al. just plublished their article ‘Fate-mapping and functional dissection reveal perilous influence of type I interferon signaling in mouse brain aging’. Very interesting read! 🔬 https://lnkd.in/d6csvhtH
Fate-mapping and functional dissection reveal perilous influence of type I interferon signaling in mouse brain aging - Molecular Neurodegeneration
molecularneurodegeneration.biomedcentral.com
To view or add a comment, sign in
-
Check out the link below to review the latest edition of "Brain Waves" highlighting the most recent news and accomplishments from Le Bonheur's Neuroscience Institute. In this issue, you'll read about Sophia Cope -- a child who is part of the first and only clinical trial in the world for SCN2A treatment held at Le Bonheur. Plus, we recently treated the first patient in Tennessee with ELEVIDYS, the first gene therapy for Duchenne muscular dystrophy. You'll also learn about our latest symposium that brought together pediatric neurosurgeons from around the world to discuss the surgical nuances of neurosurgery for nervous system tumors in children. https://ow.ly/upeU50QgV5g
Life-Changing Potential
lebonheur.org
To view or add a comment, sign in